BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Exelixis readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Exelixis's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04302025-2167@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: A Study of Multiple Therapies in
  Biomarker-selected Participants With Resectable Stages IB-III Non-small C
 ell Lung Cancer (NSCLC)\nEstimated primary completion: 30 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678673-2819@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT05678673)
DESCRIPTION:Zanzalintinib\, phase 3\, Renal Cell Carcinoma.\nStudy: Study o
 f XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic N
 on-Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5678673
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2167@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cobimetinib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Cobimetinib\, phase 2/3.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Multiple Targeted Therapies as Treatments for Participant
 s With Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cobimeti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03178552
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2167@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: A Study Evaluating the Efficacy 
 and Safety of Biomarker-Driven Therapies in Patients With Persistent or Re
 current Rare Epithelial Ovarian Tumors\nEstimated primary completion: 28 F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cobimet
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04931342
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07428616-2819@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07428616)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: A Study of Zanzalintinib in Pa
 rticipants With Recurrent or Progressive Meningioma\nEstimated primary com
 pletion: 29 February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07428616
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845786-2819@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07845786)
DESCRIPTION:Zanzalintinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Z
 anzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Sq
 uamous Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1
 5 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalin
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07845786
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2167@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Cobimetinib: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Cobimetinib\, phase 3.\nStudy: A Study in Patients Previously E
 nrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizu
 mab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cobimetinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082167-2819@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Zanzalintinib: Phase 2/3 readout est. (NCT06082167)
DESCRIPTION:Zanzalintinib\, phase 2/3.\nStudy: Study of Zanzalintinib (XL09
 2) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurr
 ent or Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated primary
  completion: August 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06082167
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943755-2819@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Zanzalintinib: Phase 2/3 readout est. (NCT06943755)
DESCRIPTION:Zanzalintinib\, phase 2/3.\nStudy: Zanzalintinib Versus Everoli
 mus in Participants With Locally Advanced or Metastatic Neuroendocrine Tum
 ors\nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06943755
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750158-2819@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20300405
DTEND;VALUE=DATE:20300406
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07750158)
DESCRIPTION:Zanzalintinib\, phase 3\, Colorectal Cancer.\nStudy: Zanzalinti
 nib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa 
 in Participants With Colorectal Cancer With Molecular Residual Disease\nEs
 timated primary completion: 5 April 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07750158
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2031@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Cabozantinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
